Sorrento to test COVID-19 candidates in preclinic via new collaboration

Sorrento Therapeutics has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of its COVID-19 therapeutic product candidates.

Dr Slobodan Paessler, John S. Dunn Distinguished Chair in Biodefense and scientific director of the Animal Biosafety Laboratory 3 at the Galveston National Laboratory, will be supervising the research.

The work will be performed in Dr Paessler’s laboratory at the University of Texas Medical Branch (UTMB), one of only two maximum containment laboratories on a university campus in the US and one of just a few such Biosafety Level 4 (BSL4) laboratories currently operating in the US.

Dr. Paessler specialises in viral pathogenesis and therapeutic agent development, and he and Dr Cheng Huang’s laboratory most recently obtained a COVID-19 viral isolate and have established the infection cell model for the SARS-CoV-2 virus.

Sorrento is currently conducting preclinical development of multiple therapeutic candidates to treat COVID-19 across its proprietary platforms, including natural killer (NK) cell therapies, neutralizing antibodies (NAbs) and soluble recombinant fusion protein traps (COVIDTRAP) to potentially inhibit the binding of SARS-CoV-2’s spike protein with host ACE2 receptors, thereby potentially preventing viral cell entry.

Elsewhere, Sorrento has entered into an exclusive license agreement with China-based antibody biopharma, Mabpharm, for the clinical development and commercialisation of the ACE-MAB fusion protein for the potential treatment of COVID-19.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Related news

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...